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Abstract  The  prognosis  for  pancreatic  cancer  is  poor,  and  early  diagnosis  is  essential  for
surgical management.  By  comparison  with  its  classic  form,  the  presence  of  acute  or  chronic
inﬂammatory  signs  will  hinder  its  detection  and  delay  its  diagnosis.  The  atypical  forms  of  acute
pancreatitis  need  to  be  known  in  order  to  detect  patients  who  require  additional  morpho-
logical investigations  to  search  for  an  underlying  tumour.  In  contrast,  pseudotumoral  forms  of
inﬂammation  (chronic  pancreatitis,  cystic  dystrophy  in  heterotopic  pancreas,  autoimmune  pan-
creatitis)  may  simulate  a  cancer,  and  make  up  5—10%  of  the  surgical  procedures  for  suspected
cancer. Faced  with  these  pseudotumoral  masses,  interpretation  relies  on  various  differentiating
signs and  advances  in  imaging.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Pancreatic  cancer  is  still  a  cancer  with  a  poor  prognosis.  With  overall  incidence  of  7  to
12/100,000,  96,000  new  cases  were  reported  in  Europe  in  2008  [1]. Unlike  other  cancers
where  the  mortality  rate  is  decreasing  (leukaemia,  colorectal  cancer,  breast  cancer),  pro-
jections  for  2012  show  the  rate  for  pancreatic  cancer  to  be  stable,  at  5.38  and  8.01/100,000
respectively  for  women  and  men,  close  to  its  rate  of  incidence  and  placing  it  in  5th  position
for  cancer  deaths  for  both  sexes  [2].  The  5-year  survival  rate  is  low  at  approximately  5%,
if  all  stages  are  considered.
At  present,  surgery  is  the  treatment  of  choice,  as  only  R0  resection  provides  hope  of
improving  survival.  Imagery  performs  well  in  diagnosis  and  locoregional  staging  of  pancre-
atic  adenocarcinoma  in  its  classic  form.  However,  there  are  still  situations  that  present
both  clinicians  and  radiologists  with  problems  when  faced  with  a  solid  mass  in  the  pan-
creas,  confronting  them  with  a  dilemma:  the  risk  of  a  false  positive  diagnosis  and  thus  of
unnecessary  surgery  or,  on  the  other  hand,  a  false  negative  diagnosis  leaving  an  adenocar-
cinoma  to  evolve  into  a  non-resectable  stage.  This  is  the  case  when  there  are  associated
acute  or  chronic  inﬂammatory  signs.
∗ Corresponding author.
E-mail address: eric.frampas@chu-nantes.fr (E. Frampas).
2211-5684/$ — see front matter © 2013 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
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Figure 2. Typical adenocarcinoma of the head of the pancreas.
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he typical form of adenocarcinoma: the
ormal situation
efore  considering  atypical  focal  solid  mass  situations,
ome  reminders  are  needed  concerning  the  main  imaging
echniques  and  the  radiological  signs  of  pancreatic  adeno-
arcinoma.
Histologically,  a  pancreatic  adenocarcinoma  shows  hypo-
ascularisation  and  marked  interstitial  ﬁbrosis.  These  two
haracteristics  are  the  basis  for  detecting  the  tumour  by
maging,  but  they  are  also  the  source  of  diagnostic  difﬁ-
ulties  when  the  tumour  occurs  on  a  pre-existing  ﬁbrous
ackground,  as  in  chronic  pancreatitis.  It  is  typically  seen
n  imaging  as  a  hypovascular  mass  with  poorly  deﬁned  con-
ours,  which  may  or  may  not  deform  the  contours  of  the
ancreas.  This  hypovascularisation  is  best  detected  by  CT  in
he  pancreatic  phase,  45  seconds  after  injection  of  2  ml/kg
odinated  contrast  agent  at  a  rate  of  3—4  ml/s,  which  gives
he  best  contrast  between  the  tumour  and  the  pancreas.
his  acquisition,  centred  on  the  pancreas  and  covering  the
rigin  of  the  celiac  trunk  and  superior  mesenteric  artery,
oth  marks  out  the  contours  of  the  lesion  as  well  as  possible
nd  in  particular  permits  ablation  possibilities  to  be  consid-
red.  It  should  be  completed  by  exploration  of  the  whole
f  the  abdominal  cavity  in  the  portal  phase  (70  s)  (Fig.  1).
hese  two  helices  provide  the  best  results  in  terms  of  detec-
ion  and  staging,  with  sensitivity  and  performance  greater
han  90%  for  the  diagnosis  of  classic  adenocarcinoma  [3].  In
RI,  the  tumour  typically  presents  as  iso-hypointense  with
1-weighting  and  iso-hyperintense  with  T2-weighting/STIR.
fter  injection,  the  frequency  of  the  tumour  hyposignal  is
aximal  in  the  arterial  phase  [4].
The  secondary  signs  associated  with  the  tumour  itself  are
ssential  for  diagnosis  and  analysis.  Dilatation  of  the  pancre-
tic  and/or  bile  duct  upstream  of  the  tumour  is  a common
ign,  present  in  more  than  80%  of  tumours  of  the  head  and
0%  of  tumours  of  the  body  of  the  pancreas  (Fig.  2)  [5].  The
opography  of  interruption  of  the  duct  is  a  major  element
igure 1. Typical adenocarcinoma of the body of the pancreas.
ontrast-enhanced axial CT slice. Hypodense mass of the pancreatic
ody with posterior extension, vascular sheathing of the celiac trunk
nd upstream atrophy.
b
T
S
f
F
Eontrast-enhanced coronal oblique CT reformation. Poorly deﬁned
ypodense mass with double biliary and pancreatic dilatation.
nd  can  be  the  principal  secondary  sign  if  the  lesion  is  iso-
ense  (11—14%  of  adenocarcinomas)  [6,7].  This  isodensity
s  moreover  combined  with  other  factors  hindering  detec-
ion  of  the  tumour:  the  higher  frequency  of  small  tumours
27%  for  tumours  smaller  than  20  mm  versus  13%  for  tumours
f  21—30  mm)  [8]  and  lower  frequency  of  secondary  signs
76%  versus  99%).  The  latter  are  dominated  in  this  case  by
tenosis  of  the  pancreatic  duct  and  dilatation  of  the  biliary-
ancreatic  duct,  in  contrast  to  parenchymal  atrophy  and
bnormal  contours,  which  are  rarer  (21  and  14%).
Upstream  parenchymal  atrophy,  of  obstructive  origin,  is
ssociated  with  82%  of  ductal  dilatations  due  to  tumours.
n  the  absence  of  a  visible  tumour,  its  segmental  character
hould  result  in  additional  morphological  examinations  (MRI
nd  endoscopic  ultrasonography),  to  explore  the  junction
etween  the  healthy  and  atrophic  parenchyma  (Fig.  3).he clinician’s and radiologist’s dilemmas
urgical  resection  is  currently  the  only  curative  treatment
or  pancreatic  adenocarcinoma.  However,  only  10—15%  of
igure 3. Typical adenocarcinoma of the head of the pancreas.
ndoscopic ultrasound. Poorly deﬁned hypoechoic mass.
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atitis  of  tumoral  origin?  Since  the  tumour  can  be  masked
by  inﬂammation  or  necrosis,  like  the  upstream  atrophyA  solid  pancreatic  mass:  Tumour  or  inﬂammation?  
patients  beneﬁt  from  resection  for  curing  the  condition.
Given  the  poor  prognosis,  delaying  surgery  at  a  potentially
resectable  stage  is  harmful,  but  on  the  other  hand,  mor-
bidity  following  pancreatic  surgery  is  still  as  much  as  41%
after  cephalic  duodenopancreatectomy  (CDP),  mainly  due
to  postoperative  ﬁstulae  and  haemorrhage,  with  a  mortality
rate  of  up  to  9%  after  CDP  and  3.5%  after  left  pancreatec-
tomy  [9—11].
The  frequency  of  CDP  revealing  benign  lesions  and  per-
formed  for  suspected  cancer  varies  between  5  and  11%
[12,13].  In  a  series  of  40  CDPs  performed  because  of  an  ini-
tial  suspicion  of  cancer  but  where  the  aetiology  was  found  in
the  end  to  be  benign,  surgery  was  motivated  by  the  discov-
ery  of  a  pancreatic  mass  in  67.5%  of  cases,  biliary  stricture
in  40%  and  false  positive  cytology  in  12.5%.  Fifty  percent
of  the  patients  had  jaundice.  The  main  aetiology  of  these
non-carcinomatous  lesions  was  lymphoplasmacytic  scleros-
ing  pancreatitis  (23.4%)  [14]. b
Figure 4. Adenocarcinoma of the head of the pancreas revealed by acu
diffuse pancreatic oedema with no focal lesion; c, d: follow-up CT scan at
can be seen which is characteristic of adenocarcinoma.743
denocarcinoma and acute pancreatitis
he  combination  of  acute  pancreatitis  and  cancer  is  unusual.
ancreatic  cancer  represents  1—2%  of  acute  pancreatitis
etiologies  and  only  3%  of  cancers  manifest  as  acute  pan-
reatitis  [15—17].  The  Association  Franc¸aise  de  Chirurgie
French  Association  of  Surgery)  series  reported  frequency  of
.1%  for  pancreatitis  among  the  1670  patients  operated  on
or  carcinoma  [18].
The  presence  of  inﬂammatory  signs  can  mask  the  under-
ying  tumour  and  delay  diagnosis  (Fig.  4a—d).  A  mean
ymptomatic  period  of  8  months  before  diagnosis  of  carci-
oma  has  been  reported,  with  a  delay  in  diagnosis  that  can
each  12  months  [15].
Can  certain  signs  help  diagnose  secondary  acute  pancre-y  oedema,  secondary  signs  become  of  great  importance.
te pancreatitis. Contrast-enhanced CT: a, b: initial CT scan showing
 3 months. A tumour lesion of the uncinate process of the pancreas
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ilatation  of  the  pancreatic  duct,  a  double  biliary  and  pan-
reatic  obstruction  or  interruption  of  the  pancreatic  duct
re  unusual  and  should  lead  to  considering  an  underlying
arcinoma  [19].  Similarly,  a  left  location  or  segmental  atro-
hy  is  a  suspect  sign  (Fig.  5a,  b).  Upstream  pseudocysts  can
e  encountered  in  both  situations,  even  if  they  are  only  seen
n  8%  of  carcinomas,  secondary  to  the  acute  pancreatitis  or
ue  to  duct  distension  and  rupture.  Their  characteristic  signs
re  comparable  [20].
Sheathing  of  the  celiac  trunk  and/or  mesenteric  artery
s  seen  in  30—60%  of  CT  scans  of  adenocarcinoma  [21].  This
ign  is  sometimes  the  main  pointer  in  the  case  of  an  iso-
ense  tumour  or  isthmic  location,  but  cannot  be  considered
s  pathognomonic,  as  it  is  also  described  in  cases  of  pan-
reatitis  [22,23].  This  is  particularly  true  of  autoimmune
ancreatitis  or  IgG4  conditions  with  extrapancreatic  lesions:
n  sclerosing  mesenteritis  and  retroperitoneal  ﬁbrosis,  fre-
uencies  have  been  reported  of  4%  and  5%  respectively
24,25].  The  location  (in  contact  with  the  pancreatitis
esions  or  distant  from  them)  and  the  stenosing  charac-
er,  or  not,  of  this  inﬁltration  are  factors  to  be  taken  into
ccount.
Finally,  5%  of  cases  of  acute  pancreatitis  where  no  ini-
ial  aetiology  is  found,  proved  to  be  caused  by  a  tumour,
hich  is  revealed  later,  thus  justifying  increased  monitor-
ng  for  patients  whose  aetiological  investigation  of  acute
ancreatitis  provides  no  clear  answer  [16].
denocarcinoma and chronic pancreatitis
an  adenocarcinoma  be  differentiated  from  a  chronic  pan-
reatitis  pseudotumour  (CP-pT)  when  confronted  with  a
ass  occurring  on  a  background  of  chronic  pancreatitis?
n  adenocarcinoma  developing  on  a  background  of  chronic
ancreatitis  is  a  rare  event,  but  one  with  a  poor  progno-
is  because  of  frequently  delayed  diagnosis.  The  estimated
p
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igure 5. Acute pancreatitis both clinically and according to laboratory
igns of acute pancreatitis with an atypical left location. No atrophy or
umour of the pancreatic body can be observed at the initial limit of inﬂE.  Frampas  et  al.
elative  risk  is  13.3%  (6.1  to  28.9%)  in  chronic  pancreatitis
nd  may  reach  69%  in  hereditary  pancreatitis  [26].
The  clinical  presentation  is  identical  (pain,  weight  loss,
aundice).
orphological imaging
adiologically,  the  classic  signs  are  also  misleading.  The
ouble  duct  obstruction  suggestive  of  adenocarcinoma  is
resent  in  36—50%  of  cases  of  chronic  pancreatitis  oper-
ted  for  suspected  cancer  [13,27].  In  a series  of  35  cases
f  pseudotumoral  pancreatitis,  25  (71.5%)  presented  as  a
ocal  lesion,  and  involved  the  head  region  in  more  than  80%
f  those  cases.  In  the  context  of  chronic  pancreatitis,  calci-
cations  displaced  by  the  mass  are  a classic  sign  suggesting
 carcinoma  (Fig.  6a—d).  However,  the  presence  of  intrale-
ional  calciﬁcations,  classically  described  in  CP-pT,  was  only
etected  in  the  end  in  14—28%  of  these  pseudotumours
28,29].
Pancreatic  adenocarcinoma  is  a  tumour  with  a  hypoxic,
ypovascular  ﬁbrous  component,  as  is  the  ﬁbrosis  of  chronic
ancreatitis.  Confusion  may  also  occur  on  biopsy  specimens
f  the  carcinoma  is  well  differentiated  or  the  ﬁbrous  stroma
bundant.  While  a  signiﬁcant  reduction  in  microvascular
ensity  has  been  demonstrated  in  cancerous  and  chronic
ancreatitis  tissue  compared  with  normal  pancreatic  tis-
ue  (respectively  by  a  factor  of  4  and  5),  the  variations
etween  the  pathological  tissues  are  similar  and  insignif-
cant  [30].  Similarly,  the  ﬁbroblastic  stromal  cells  in  the
brous  tissue  of  the  tumour  have  characteristics  identical
o  those  of  the  pancreatic  stellate  cells  present  in  chronic
ancreatitis  and  the  hub  of  pancreatic  ﬁbrosis  [31].  A  num-
er  of  additional  histopathological  and  immunohistological
arameters  are  therefore  necessary  [32]. It  is  thus  easy  to
nderstand  the  difﬁculties  of  differentiating,  in  imaging,
etween  a CP-pT  focus  and  an  adenocarcinoma  in  chronic
ancreatitis.
 values. Contrast-enhanced axial CT slice: a: initial CT scan showing
 dilatation of the pancreatic duct; b: follow-up after 9 months: a
ammation, with upstream dilatation of the pancreatic duct.
A  solid  pancreatic  mass:  Tumour  or  inﬂammation?  745
Figure 6. Calciﬁcation, chronic pancreatitis and adenocarcinoma: contrast-enhanced CT scans: a: hypodense nodule in the uncinate
process of the pancreas with central calciﬁcation. This is highly suspect of carcinoma. The biopsies performed and close monitoring led
to the conclusion of focal chronic pancreatitis; b: multiple disseminated calciﬁcations in the head on focal chronic pancreatitis; c, d:
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Chronic pancreatitis macrocalciﬁcations of the head are absent wit
Functional imaging
Functional  imaging  developed  to  search  for  speciﬁc  biomark-
ers  when  classic  morphological  criteria  are  found  wanting.
Various  methods  based  on  tissue  enhancement  kinetics  after
injection  of  a  contrast  agent  have  been  studied  to  differen-
tiate  lesions.
Ultrasonography
In  ultrasound,  the  morphological  criteria  are  classically
based  on  the  echo  structure,  the  limits  of  the  lesion,  associ-
ated  duct  abnormalities,  the  presence  of  adenopathies  and
any  vascular  invasion.  With  these  simple  criteria,  sensitiv-
ity  of  73.2%  and  speciﬁcity  of  83.3%  have  been  reported
with  endoscopic  ultrasound  alone  [33].  Its  diagnostic  per-
formance  varies  between  63  and  76%  [34].  With  injection
of  a  contrast  agent  tissue  vascularisation  can  be  explored,
due  to  its  purely  intravascular  distribution,  an  adenocarci-
noma  being  typically  hypovascular  with  contrast-enhanced
ultrasound,  in  contrast  to  the  presence  of  parenchymo-
graphic  enhancement  in  a  CP-pT.  Hypovascularisation  is  thus
t
n
g
c mass of the head of the pancreas with posterior celiac inﬁltration.
mour inﬁltration.
 sensitive  and  speciﬁc  criterion  (91.1%  and  93.3%)  for
he  diagnosis  of  adenocarcinoma  [35].  On  the  other  hand,
he  presence  of  moderate,  continuous  lesion  enhancement,
sovascular  with  the  adjacent  parenchyma,  provides  the
iagnosis  of  CP-pT,  with  sensitivity  of  88.6%  and  speciﬁcity
f  97.8%,  a positive  predictive  value  of  91.2%  and  overall
erformance  of  96%  [28].  Old,  very  ﬁbrous  forms  of  CP-pT
an  however  be  hypovascular  [36].  Improvement  in  detec-
ion  with  endoscopic  ultrasonography  of  arterial  and  venous
essels  in  duplex  mode  after  injection  improves  diagnostic
erformance,  with  sensitivity  of  91.5%  for  adenocarcinoma
nd  speciﬁcity  of  93.3%  for  CP-pTs  [33]. The  addition  of  the
armonic  mode  potentiates  vascular  exploration  and  the
tudy  of  pancreatic  diffusion  by  searching  for  slow  ﬂows,
hile  avoiding  Doppler  artefacts.  The  heterogeneous  hypo-
r  avascular  character  of  adenocarcinomas  is  the  opposite  of
he  homogeneous  isovascular  character  of  CP-pTs  [37].  Two
tudies  have  shown  the  importance  of  this  hypovascular  cri-
erion  (sensitivity  89—96%  and  speciﬁcity  88—64%)  for  diag-
osis  of  adenocarcinoma  [38,39]. Similarly,  using  a  second-
eneration  product,  Sonazoid®, marketed  in  Asia,  95%  of
arcinomas  were  hypovascular  as  against  8%  of  CP-pTs  [40].
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While  these  previous  criteria  are  based  on  purely  visual
nalysis  of  enhancement,  it  is  now  also  possible  to  study
nhancement  curves  quantitatively.  There  are  as  yet  not
any  results.  Kersting  et  al.  have  shown  that,  using
onovue® with  transcutaneous  ultrasound,  the  adenocar-
inomas  had  a  longer  contrast  medium  transit  time  and
 longer  time  to  peak  than  CP-pTs,  for  which  the  time
o  peak  was  similar  to  or  slightly  longer  than  for  nor-
al  parenchyma.  However,  maximum  intensity  and  the
rea  under  the  enhancement  curve  were  not  signiﬁcantly
ifferent  [41].  Another  study  using  Sonazoid® with  endo-
copic  ultrasonography  reported  a  signiﬁcant  difference  in
eak  intensity  between  carcinoma  and  autoimmune  pan-
reatitis,  unlike  the  time  to  peak[42].  Adding  exploration
f  vascular  enhancement  kinetics  and  vascular  behaviour
eems  to  increase  diagnostic  performance  compared  with
he  standard  B-mode,  thus  allowing  an  improvement  from
2.6%  to  approximately  94.7%  in  the  aetiological  study  of
ancreatic  masses  [43].
T  scan
nlike  the  purely  vascular  distribution  of  ultrasound  contrast
gents  such  as  Sonovue®,  the  distribution  of  iodinated  con-
rast  agents  is  both  vascular  and  extracellular  interstitial.
t  would  thus  seem  to  be  potentially  useful  for  explor-
ng  and  discriminating  between  cancerous  and  pancreatitis
issue  (the  vascular  and  ﬁbrous  aspects).  The  purely  mor-
hological  appearance  is  rarely  sufﬁcient  for  distinguishing
etween  adenocarcinoma  and  a  chronic  pancreatitis  pseu-
otumour,  especially  as  the  preferred  site  of  CP-pTs  in  the
ead  is  also  associated  with  effects  on  one  or  both  ducts,
hich  can  mimic  a  carcinoma  [28,33].  Comparison  of  the
ascular  enhancement  dynamics  and  histological  factors  has
hown  a  positive  correlation  between  the  absolute  degree
f  enhancement  in  the  arterial  phase  (30  s)  and  angio-
enesis  factors  (microvascular  density  and  VEGF  level)  and
he  opposite  with  the  degree  of  ﬁbrosis  [44].  The  pres-
nce  of  ﬁbrosis  is  responsible  for  delayed  enhancement
elated  to  the  extravascular-extracellular  component.  This
articularly  explains  the  usefulness  of  undertaking  a  delayed
hase  scan  (4  min)  for  tumour  detection  if  the  tumour  is  iso-
ense  [6].  Can  enhancement  proﬁles  be  established,  then?
omparison  in  a  triphasic  scan  after  injection  of  contrast
gent  differentiated  three  types  of  curves:  an  enhancement
eak  in  the  early  phase  (30—40  s)  followed  by  progres-
ive  washout  for  the  normal  parenchyma,  a  peak  moved
o  60—70  s  in  the  context  of  chronic  pancreatitis  followed
y  progressive  washout,  and  ﬁnally  progressive  enhance-
ent  for  the  adenocarcinoma.  Comparison  of  the  curves
hows  a  performance  of  82—90%  for  differentiating  chronic
ancreatitis  from  cancer,  with  sensitivity  of  82—94%  and
peciﬁcity  of  83—90%  [45].  This  is  consistent  with  a  more
ecent  study  where  the  positive  predictive  value  of  a  pro-
ressive  enhancement  curve  followed  by  a  plateau  without
econdary  washout  was  92%  for  the  diagnosis  of  adeno-
arcinoma  (sensitivity  74.2%,  speciﬁcity  93.7%).  It  should
owever  be  noted  that  while  the  curve  proﬁle  was  observed
n  23/25  patients  with  carcinoma,  it  was  also  detected  in
he  upstream  atrophic  parenchyma  [46]. Perfusion  tech-
iques  also  allow  angiogenesis  parameters  to  be  studied.
he  perfusion  parameters  of  adenocarcinoma  compared
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ith  healthy  pancreas  (blood  ﬂow  and  volume,  permeability
rea)  are  signiﬁcantly  decreased  [47,48],  and  reduction  in
hem  is  more  marked  for  adenocarcinoma  than  for  chronic
ancreatitis  [49].  Proﬁles  and  quantitative  studies  have  been
ombined  by  Lu  et  al.,  showing  a  signiﬁcant  difference  in
he  enhancement  proﬁle  and  more  pronounced  reduction  in
hese  three  parameters  in  carcinoma  compared  with  CP-pTs
50].
RI
ith  its  multiparametric  study  can  MRI  help  us  go  further?
y  combining  cholangiographic  exploration  with  injection
f  gadolinium  chelates,  sensitivity  has  been  reported  of
3%  and  speciﬁcity  of  87%  for  distinguishing  between  the
wo  conditions.  The  presence  of  a hypointense  lesion  with
elatively  well-deﬁned  contours  in  the  portal  phase  after
adolinium  injection  seems  to  be  the  most  discriminating
actor  for  diagnosis  of  carcinoma  [51].  Studies  of  enhance-
ent  kinetics  after  injection  of  gadolinium  chelates  have
iven  similar  results  to  CT  results  but  are  still  difﬁcult  to  use.
radual  enhancement  of  the  lesion  was  seen  in  both  cases.
nly  the  percentage  of  enhancement  in  the  delayed  phase
as  signiﬁcantly  different,  being  more  marked  in  the  case
f  carcinoma  [52]. This  was  also  observed  in  the  shape  of
he  intensity/time  curve  as  progressive  enhancement  until
—3  min  after  injection,  followed  by  washout  or  a  plateau.
hile  the  presence  of  a  secondary  plateau  was  only  seen
ith  carcinomas,  there  was  always  an  overlap  with  CP-pTs
n  the  case  of  secondary  washout.  For  CP-pTs,  help  was  pro-
ided  by  detection  of  an  identical  curve  in  at  least  one  other
egion  of  the  pancreas  [53].
Adapted  from  endoscopic  retrograde  cholangiopancre-
tography,  MRI  cholangiopancreatography  performs  well  for
iagnosing  pancreatic  cancer,  with  sensitivity  of  84%  and
peciﬁcity  of  97%  [54]. Using  duct  morphology  criteria,  a
ormal  or  regularly  stenotic  duct  visualised  within  the  mass
s  a  sign,  with  good  sensitivity  at  85%  and  speciﬁcity  at  96%,
or  diagnosis  of  CP-pT  (Fig.  7a,  b)  [55].
Diffusion  imaging  is  used  more  and  more  in  oncology.  In
denocarcinoma,  this  diffusion  appears  to  be  restricted  by
irtue  of  its  ﬁbrous  character.  Exploration  with  a high  b  value
1,000  s/mm2) appears  to  be  effective  for  detecting  pancre-
tic  adenocarcinoma,  with  sensitivity  of  96.2%  and  speci-
city  of  98.6%  [56]. This  restriction  will  also  be  seen  with
P-pTs.  On  the  other  hand,  the  quantitative  data  appear
o  be  more  disparate  [57].  Carcinomas  have  mean  ADC  val-
es  which  are  signiﬁcantly  lower  than  those  of  the  normal
ancreas  and  CP-pTs  [58].  However,  depending  on  the  differ-
ntiation  and  the  ﬁbre  content  of  the  tumour,  the  ADC  values
alculated  overlap  between  the  various  conditions  [59].  As
n  all  diffusion  protocols,  the  lack,  especially,  of  standardisa-
ion  makes  comparative  analysis  of  literature  data  difﬁcult,
he  calculated  values  varying  depending  on  the  sequences
nd  the  b  values  used  [60]. The  ADC  of  CP-pTs  varies  between
.69—1.23,  2.09,  1.04—1.35  10—3 mm2/s  for  the  b  values
sed  of  500,  600  and  1,000  s/mm2 respectively  [61—63].
MRI  perfusion  data  are  similar  to  CT  data:  the  parameters
xtracted  from  pharmacokinetic  models  of  enhancement
urves  (Ktrans: volume  transfer  coefﬁcient,  the  fractions
f  volume  respectively  occupied  by  the  vascular  and
xtravascular-extracellular  spaces)  reﬂect  the  respective
A  solid  pancreatic  mass:  Tumour  or  inﬂammation?  747
Figure 7. Focus of chronic pancreatitis: penetrating duct sign: a: contrast-enhanced coronal CT reformation. Hypodense area of the
pancreatic isthmus. Microcalciﬁcations of the body of the pancreas in chronic calciﬁc pancreatitis. Visualisation of the pancreatic duct
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parenchyma of the isthmus.
components  of  vascular  space  (and  therefore  the  density
of  the  microvasculature)  and  ﬁbrosis.  The  same  difﬁculties
will  be  encountered  in  differentiating  adenocarcinoma  from
CP-pT.  The  signal  intensity/time  curves  have  a  comparable
proﬁle.  The  difference  may  be  found  in  the  microvascular
density  (MVD)  between  the  two  states,  as  reﬂected  by  the
parameters  f  (distribution  fraction)  and  ve (fraction  of  the
volume  occupied  by  the  extravascular-extracellular  space)
[64].
While  results  look  promising,  regardless  of  the  technique
used,  it  is  necessary  to  standardise  acquisition  protocols  and
kinetic  models  to  determine  reliable  quantitative  data  for
use  in  everyday  practice.
Biopsies and cytology
The  identiﬁcation  of  masses  or  pseudotumours  in  chronic
pancreatitis  lesions  is  a  source  of  diagnostic  problems,  irre-
spective  of  the  type  of  imaging  used.  Cytological  samples
obtained  during  endoscopy  often  provide  the  deﬁnitive  evi-
dence  swaying  the  decision.  Diagnostic  accuracy  is  high
between  80  and  90%  for  diagnosis  of  adenocarcinoma.  The
results  are  not  so  good  however  when  there  is  underlying
chronic  pancreatic  disease,  with  lower  sensitivity  (54—74%
vs.  89—91%)  [65,66].  To  improve  the  quality  of  sampling,  per-
cutaneous  biopsy  can  also  be  performed  with  a  high  success
rate  and  low  risk  of  complications  [67].
Carcinoma and groove pancreatitis
The  duodenopancreatic  groove  can  be  the  site  of  inﬁltration
by  a  pancreatic  carcinoma,  but  also  of  pancreatitis  lesions  in
cystic  dystrophy  in  heterotopic  pancreas  (CDHP).  The  prin-
ciple  feature  of  CDHP  is  the  presence  of  cysts  surrounded  by
inﬂammation  and  ﬁbrosis  in  the  wall  of  the  intestine,  inter-
spersed  with  heterotopic  pancreas  lobules  and  ducts  [68].
Clinical  signs  are  similar  in  both  cases  (pain  91%,  weight  loss
73%,  jaundice  13%).  In  imaging,  inﬁltration  of  the  groove
appears  hypovascular  after  injection,  and  in  MRI,  T1  and
T2-weighted  sequences  do  not  discriminate.  The  principal
[
c
ﬁ
ar pancreatic duct, but without stenosis, within inﬁltration of the
ign  is  the  detection  of  cysts,  whether  in  a  CT  scan  or
R  image  (Fig.  8a,  b  and  9a,  b),  that  will  hallmark  CDHP.
ysts  were  present  in  CT  scans  in  19/20  patients  with  CDHP,
ith  a mean  of  4.2  (two  to  seven  cysts)  and  ranging  in  size
etween  6.8  and  14.7  mm,  as  against  a  single  cyst  detected
n  one  patient  in  a  series  of  nine  adenocarcinomas.  One  sin-
le  patient  had  CDHP  without  cysts  being  seen  in  imaging,
ut  found  in  a  histopathological  examination  [69,70]. Rare
olid  forms  of  CDHP  have  been  reported.
Conversely,  where  there  is  inﬁltration  of  the  groove,
ome  signs  should  cast  a  doubt  on  a  diagnosis  of  CDHP  and
ncourage  caution:  the  presence  of  biliary  dilatation,  found
umulatively  in  100%  of  cases  of  carcinoma  compared  with
8%  of  CDHP  cases  [69—71],  involvement  of  the  gastroduo-
enal  artery  (sheathing,  stenosis  or  occlusion),  the  absence
f  alcohol  consumption  (present  in  86%  of  CDHP  cases),  late
ppearance  after  50  years  of  age.  Endoscopic  ultrasonogra-
hy  can  then  provide  information  by  detecting  any  cysts  in
he  duodenal  wall  or  by  allowing  cytological  samples  to  be
btained.  One  case  of  carcinoma  on  a  background  of  CDHP
as  been  reported  [72].
denocarcinoma and autoimmune
ancreatitis (AIP)
utoimmune  pancreatitis,  a  chronic  inﬂammatory  process  of
he  pancreas,  is  rare  (1.86  to  6.6%  of  the  causes  of  chronic
ancreatitis).  Two  histological  and  clinical  conditions  have
radually  been  identiﬁed.  Type  1  (lymphoplasmacytic  scle-
osing  pancreatitis),  more  common  in  Asia,  is  found  in
n  autoimmune  context  of  IgG4-related  systemic  diseases,
ncluding  in  60%  of  cases  of  other  autoimmune  diseases
uch  as  cholangitis,  autoimmune  hepatitis,  or  Sjögren’s  syn-
rome  (Fig.  10a—g).  It  combines  a  dense  lymphoplasmacytic
nﬁltrate,  positive  with  IgG4  immunostaining,  ﬁbrosis  and
enulitis,  and  is  associated  with  raised  serum  IgG4  levels
73—75]. Type  2,  the  most  common  in  Western  countries,  is
haracterised  by  an  isolated  pancreatic  lesion  with  ductal
brosis  and  granulocytic  epithelial  lesions.  Association  with
n  inﬂammatory  condition  of  the  digestive  tract  is  reported
748  E.  Frampas  et  al.
Figure 8. Cystic dystrophy in heterotopic pancreas. Pseudotumour inﬁltration of the pancreatic groove: a: contrast-enhanced coronal CT
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geformation. Inﬁltration of the groove, chronic pancreatitis lesion
: corresponding T2-weighted RARE MRCP sequence. Obstructive d
ancreas. Groove cysts indicating CDHP.
n  20-30%  of  cases.  The  IgG4  concentration  is  normal.  A
umber  of  clinical,  laboratory  test,  histological  and  imaging
riteria  have  been  put  forward  for  diagnosis  of  AIP  (HISORt
riteria,  Asian  consensus  diagnostic  criteria)  [76—78].
Nearly  10%  of  presumed  carcinomatous  masses  surgically
perated  have  been  composed  of  pseudotumoral  forms  of
ancreatitis,  nearly  half  of  which  were  thought  to  be  focal
orms  of  autoimmune  pancreatitis  [79].  These  focal  forms
onstitute  up  to  67%  of  AIP  series,  with  involvement  pre-
ominantly  of  the  head  [80].  There  are  many  reasons  for
hese  resections:  ignorance  of  these  atypical  forms,  absence
f  preoperative  measurement  of  IgG4,  false  positives  from
reoperative  cytological  samples.  The  rate  of  histological
alse  positives  for  carcinoma  or  suspected  carcinoma  is  high,
eaching  32%  for  biopsies  and  41%  for  ﬁne  needle  cytology
81].
Increase  in  serum  IgG4  concentration  is  an  important
oint  in  the  diagnostic  criteria  for  type  1,  but  is  absent  in
i
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igure 9. Groove carcinoma. Inﬁltration of the pancreatic groove: a: 
roove. Associated dilatation of both ducts; b: corresponding T2-weighthe head with calciﬁcations and dilatation of the pancreatic duct;
ion of the pancreatic duct due to duct lithiasis in the head of the
ype  2,  the  most  common  form  in  the  West.  A  concentra-
ion  higher  than  135  mg/dl  seems  to  have  sensitivity  of  97%
nd  speciﬁcity  of  95%  for  diagnosis  of  AIP  [82], but  high  con-
entrations  have  also  been  described  with  carcinoma  (10%)
83]. Increased  levels  of  tumour  markers  (CEA,  CA19-9)  can
e  encountered  in  AIP.
Certain  imaging  criteria  may  attract  our  attention
ecause  they  are  more  frequent  in  AIP:  both  early  and
elayed  homogeneous  enhancement  of  the  lesion,  close  to
hat  of  normal  parenchyma,  peripheral  pseudocapsule,  a
uct  visible  in  the  mass  with  an  hourglass  stenosis,  absence
f  upstream  atrophy  or  marked  dilatation  of  the  pancreatic
uct  (<  4  mm),  multifocal  involvement,  absence  of  contact
ascular  involvement  [74,84].
Given  the  autoimmune  context,  the  detection  of  other
ntra-  or  extrapancreatic  lesions  will  be  of  considerable
mportance.  Except  in  particular  contexts  (intraductal  pap-
llary  mucinous  tumours  of  the  pancreas),  macroscopic
contrast-enhanced axial CT slice. Homogeneous inﬁltration of the
ed RARE MRCP sequence. No visible cyst.
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Figure 10. Atypical autoimmune pancreatitis pseudotumour of the head of the pancreas. Discovery, due to abdominal pain, of a hypoechoic
nodule of the head: a: contrast-enhanced ultrasound, image at 25 s: well-deﬁned hypoechoic nodule. Early homogeneous enhancement;
b—d: axial CT with injection. Peribiliary inﬁltration of the left hepatic lobe. Isodense nodule of the head of the pancreas. Periarterial
sheathing inﬁltration of the superior mesenteric artery and aorta; e, f: diffusion MRI at b 600. Bifocal pancreatic lesion with head and body
hyperintensity; g: axial T1-weighted MRI with injection: periaortitis. In all, multifocal lesions due to an IgG4 pathology conﬁrmed by liver
biopsy.
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ultifocal  forms  of  adenocarcinoma  are  unusual,  even  if  a
icroscopic  multifocal  lesion  or  identical  mutations  have
een  detected  in  0—6%  of  total  pancreatectomy  specimens
85,86].  Diffusion  MRI  shows  a  reduction  in  the  ADC  in  AIP,
ith  values  lower  than  those  of  pancreatic  carcinoma  or
he  healthy  pancreas.  However,  the  optimal  discrimination
hreshold  values  vary  depending  on  the  series  and  the  diffu-
ion  sequences  (0.88  to  1.075  ×  10−3 mm2/s)  and  make  them
till  difﬁcult  to  use  in  practice.  Detection  of  hyperintense
iffuse  or  multifocal  lesions  and  longitudinal  morphology,
c
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igure 11. PET appearance of pancreatic and extrapancreatic binding
inding; c: mediastinal lymph node binding in associated sarcoidosis.ore  than  measurement  of  the  ADC,  are  the  elements
elping  with  diagnosis,  in  contrast  to  the  solitary,  nodular
haracter  of  adenocarcinoma  [87,88].  FDG-PET  is  also  use-
ul  here.  While  lesional  binding  is  found  in  virtually  100%  of
ases  of  AIP  and  in  73—82%  of  cancers,  the  most  interesting
ifferences  concern  extra-lesional  binding:  in  AIP  and  can-
er,  multifocal  pancreatic  binding  is  50%  versus  5%,  diffuse
ancreatic  binding  53%  versus  3%,  salivary  binding  35%  versus
%  and  renal  binding  17%  versus  0%,  respectively  (Fig.  11a—c)
89,90].
 in autoimmune pancreatitis: a: pan-glandular binding; b: salivary
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between  them,  no  matter  what  technique  is  used
(ultrasound,  CT,  perfusion  or  diffusion  MRI).
• A  rigorous  multimodal  approach  to  the  signs
and  symptoms  looking  for  any  discordant  feature
is  essential  in  order  to  obtain  endoscopic  or
percutaneous  histopathological  samples  if  there  is
any  doubt.
• The absence  of  cysts  or  no  alcohol  consumption
should  lead  to  a  possible  diagnosis  of  CDHP  being
questioned  where  there  is  inﬁltration  or  groove
pancreatitis,  and  result  in  a subjacent  inﬁltrating
tumour  being  sought.
Clinical case
A  50-year-old  male  patient  referred  for  jaundice  and  in
whom  a  lesion  of  the  head  of  the  pancreas  was  discovered.
CT  exploration  70  s  (Figs.  12  and  13)  and  3  min  (Fig.  14)
after  injection.
Coronal  RARE  MRCP  sequence  also  performed  (Fig.  15).
Figure 12. Axial CT centred on the pancreas 70 s after injection.
Pancreatic duct discretely visible.A  solid  pancreatic  mass:  Tumour  or  inﬂammation?  
Response  to  corticosteroid  treatment  is  one  of  the  diag-
nostic  criteria  for  AIP.  A  therapeutic  test  for  this  can  be
included  in  the  diagnostic  strategy  for  AIP  when  the  criteria
are  highly  suggestive  or  compatible  but  not  deﬁnitive  [91].
In  the  case  of  atypical  masses  which  could  suggest  AIP  (a
young  patient,  absence  of  risk  factors,  associated  with  other
autoimmune  diseases,  absence  of  weight  loss  or  raised  CA19-
9),  a  therapeutic  test  of  15  days  of  corticosteroids  could  be
included  in  the  diagnostic  process  [92].  However,  accord-
ing  to  Levy  et  al.,  this  should  only  be  envisaged  in  cases  of
an  atypical  mass  after  at  least  two  biopsies  containing  no
tumour  cells  have  been  carried  out  by  experienced  special-
ists  [93].  These  biopsies  are  the  major  determinant  for  the
diagnosis  of  focal  AIP  in  type  2  lesions.  However,  they  are
still  difﬁcult  to  interpret;  diagnosis  with  certainty  requires
the  presence  of  both  pancreatic  tissue  and  ducts,  elements
that  are  only  present  in  26—44%  of  biopsies  [76,94].  It  should
also  be  noted  that  some  cases  of  synchronous  carcinoma  and
AIP  have  been  reported  [95].
Conclusion
Imaging  techniques  are  effective  in  the  diagnosis  of  clas-
sic  forms  of  pancreatic  adenocarcinoma.  Other  than  in
these  classic  forms,  detailed  analysis  of  clinical  and  imaging
signs  and  symptoms  should  be  undertaken  to  determine  the
atypical  form,  avoid  primary  diagnostic  errors  and  provide
direction  for  more  in-depth  investigations.  While  functional
imaging  can  reveal  signiﬁcant  differences  between  adeno-
carcinoma  and  pancreatitis  pseudotumours,  its  utilisation  in
current  practice  is  still  limited  for  individual  use.  Eliminat-
ing  diagnosis  of  carcinoma  must  be  the  primary  objective  in
management  of  these  patients,  given  its  higher  frequency
in  comparison  with  atypical  forms  of  inﬂammation  and  its
poor  prognosis.  Biopsies  are  an  effective  means  of  removing
doubts  concerning  diagnosis.
TAKE-HOME  MESSAGES
• Pancreatic  adenocarcinoma  is  still  a  cancer  with  a
poor  prognosis.  Currently,  only  R0  surgical  resection
can  provide  hope  of  better  survival.
• Radiological  investigations  (CT,  MRI)  are  effective  for
the  diagnosis  and  staging  of  adenocarcinoma  in  its
classic  form.
• Acute  pancreatitis  associated  with  cancer  is
unusual.  Any  acute  pancreatitis  where  the  aetiology
has  not  been  found  or  which  has  an  atypical
presentation  (left  location,  duct  dilatation  or
segmental  atrophy)  must  be  further  investigated
(endoscopic  ultrasonography,  close  monitoring).
• In  5  to  11%  of  cephalic  duodenopancreatectomies
reported  for  a  solid  mass  presumed  to  be  a  tumour,
the  cause  is  benign.  The  main  aetiologies  are  chronic
pancreatitis  foci  or  focal  autoimmune  pancreatitis.
While  differences  exist,  particularly  in  the  analysis
of  curves  of  enhancement  kinetics  after  injection,
the  common  ﬁbrous  character  of  these  different
conditions  still  makes  it  difﬁcult  to  differentiate Figure 13. Axial CT centred on the head of the pancreas 70 s
after injection. Irregular hypodense mass in the anterior part of the
head.
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Figure 14. Axial CT centred on the head of the pancreas 3 min
(delayed phase) after injection. Progressive enhancement of the
mass.
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Figure 16. Axial CT centred on the head of the pancreas 70 s after
injection performed 3 weeks after the start of corticosteroid treat-
ment. Deﬁnite dilatation of the pancreatic duct. Contrast uptake
by the biliary stenosis of the lower common bile duct.Endoscopic  ultrasonography  performed  with  ﬁne  needle
iopsy.  The  histopathological  results  were  as  follows:  inﬂam-
atory  cells,  no  tumour  cells.  IgG4  concentration:  265  (nl
80).  A  course  of  15  days  corticosteroid  treatment  was
egun.
Three  weeks  after  the  start  of  corticosteroid  treatment
 follow-up  CT  scan  was  performed  to  monitor  changes
Figs.  16  and  17).
uestions
.  How  do  you  analyse  the  initial  images?.  Do  you  agree  with  the  proposed  diagnosis  of  autoimmune
pancreatitis?
igure 15. MRCP with coronal incidence and RARE sequence. Bile
uct dilatation with stenosis of the intrapancreatic bile duct without
ffecting the pancreatic duct.
Figure 17. Corresponding coronal MPR centred on the head of the
p
c
A
1
2ancreas 70 s after injection. Long, tight stenosis of the intrapan-
reatic bile duct.
nswers
.  The  initial  CT  scans  show  poorly  limited  discretely  hypo-
dense  inﬁltration  of  the  anterior  part  of  the  head  of  the
pancreas,  inﬁltrating  the  fat  in  front  of  the  duodenum.
No  effect  on  the  pancreatic  duct  can  be  seen  but  there
is  clear  dilatation  of  the  bile  ducts  with  an  intrapan-
creatic  stenosis.  The  atypical  features  for  diagnosis  of
autoimmune  pancreatitis  are  irregular  inﬁltration  of  the
pericephalic  fat  and,  particularly,  late  enhancement  of
the  lesion  suggesting  a  marked  ﬁbrous  character.  A  high
IgG4  concentration  is  possible  in  10%  of  carcinomas.
.  The  images  at  3  weeks  show  an  increased  effect  on
the  bile  ducts  and  above  all  on  the  pancreatic  duct,
which  does  not  ﬁt  the  diagnosis  of  AIP  and  means
that  this  diagnosis  should  be  rapidly  reconsidered.  New
A  solid  pancreatic  mass:  Tumour  or  inﬂammation?  
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[Figure 18. CT scan with injection. Needle biopsy via an anterior
approach of the pancreatic mass.
percutaneous  biopsies  (Fig.  18)  led  to  a  diagnosis  of  pan-
creatic  adenocarcinoma.
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